Ordering RecommendationRecommendations when to order or not order the test. May include related or preferred tests.
Preferred initial screening test for prostate cancer in conjunction with digital rectal exam. Use to monitor patients for recurrence of cancer.
MnemonicUnique test identifier.
PSA SCN
MethodologyProcess(es) used to perform the test.
Quantitative Electrochemiluminescent Immunoassay
PerformedDays of the week the test is performed.
Sun-Sat
ReportedExpected turnaround time for a result, beginning when ARUP has received the specimen.
Within 24 hours
New York DOH Approval StatusIndicates test has been approved by the New York State Department of Health.
This test is New York DOH approved.
Specimen Required
Patient Preparation
Collect
Serum Separator Tube (SST) or Plasma Separator Tube (PST). Also acceptable: Plain Red, Green (Sodium or Lithium Heparin), Lavender (EDTA), or Pink (K2EDTA).
Specimen Preparation
Transport 1 mL serum or plasma in an ARUP Standard Transport Tube. (Min: 0.5 mL)
Reference IntervalNormal range/expected value(s) for a specific disease state. May also include abnormal ranges.
0.0-4.0 ng/mL
Interpretive DataBackground information for test. May include disease information, patient result explanation, recommendations, details of testing, associated diseases, explanation of possible patient results.
The Roche PSA electrochemiluminescent immunoassay is used. Results obtained with different test methods or kits cannot be used interchangeably. The Roche PSA method is approved for use as an aid in the detection of prostate cancer when used in conjunction with a digital rectal exam in men age 50 and older. The Roche PSA is also indicated for the serial measurement of PSA to aid in the prognosis and management of prostate cancer patients. Elevated PSA concentrations can only suggest the presence of prostate cancer until biopsy is performed. PSA concentrations can also be elevated in benign prostatic hyperplasia or inflammatory conditions of the prostate. PSA is generally not elevated in healthy men or men with non-prostatic carcinoma.
Compliance Category
FDA
NoteAdditional information related to the test.
This test should be ordered for screening purposes for Medicare patients only.
Hotline History
N/A
CPT CodesThe American Medical Association Current Procedural Terminology (CPT) codes published in ARUP's Laboratory Test Directory are provided for informational purposes only. The codes reflect our interpretation of CPT coding requirements based upon AMA guidelines published annually. CPT codes are provided only as guidance to assist clients with billing. ARUP strongly recommends that clients confirm CPT codes with their Medicare administrative contractor, as requirements may differ. CPT coding is the sole responsibility of the billing party. ARUP Laboratories assumes no responsibility for billing errors due to reliance on the CPT codes published.
* Component test codes cannot be used to order tests. The information provided here is not sufficient for interface builds; for a complete test mix, please click the sidebar link to access the Interface Map.
AliasesOther names that describe the test. Synonyms.
PSA
Screen for Prostate Specific Ag
sPSA
Prostate Specific Antigen, Total - Medicare Screening
Chat
Feedback
